anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide an adiponectin secretion promoter capable of inducing adiponectin secretion, and an anti-arteriosclerosis agent, an anti-obesity agent, an antidiabetic mellitus agent, a food additive, a functional food and a feed additive containing the adiponectin secretion promotor.  <P>SOLUTION: This adiponectin secretion promoter contains a cycloartane type triterpene or a cycloartenol which is its derivative, and/or (24S)-24,25-dihydroxycycloartanol or its derivatives obtained by extracting rice bran. The adiponectin secretion promoter can promote the secretion of more adiponectin from lipid cells. Therefore, it is possible to aim at the prevention and improvement of diseases considered to be caused by the reduction of adiponectin secretion, e.g. various circulatory diseases such as arteriosclelosis, etc., lifestyle-related diseases such as diabetic mellitus, etc., or obesity.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Dye compositions are prepd. by (a) at least partly oxidising one or more oxidation bases, opt. in the presence of one or more couplers for the base, in an alkaline medium, pref. ammonia, and (b) freeze drying or spray drying the soln. contg. the reaction mixt. at =60 degrees C. Used for dyeing human hair. The dye compositions give uniformly dyed hair, and are safe to use than the dye solns. from which they are prepd. A wide range of oxidation bases can be used.
PROBLEM TO BE SOLVED: To provide an active oxygen scavenger for formulation into cosmetic preparations, pharmaceuticals, quasi-drugs, foods and the like. SOLUTION: This active oxygen scavenger contains a solvent extract of a specified plant, such as Cinnamomum sintok B1. in nomenclature (Sintok in Indonesian), Strychnos ligustrina B1. in nomenclature (Widoro Laut in Indonesian), Parameria Laevigata in nomenclature (Juss.), Moldenke in nomenclature (Kayu rapat in Indonesian), Euginia polyantha Wight. in nomenclature (Babakan salam in Indonesian), Eugenia aromatica 0.K. in nomenclature (Cengkeh in Indonesian), Quercus lusitanica Lamk in nomenclature (Majakani in Indonesian), Elaeocarpus ganitrus Roxb. in nomenclature (Jenitri in Indonesian). This active oxygen scavenger, by virtue of its excellent active oxygen scavenging activity, is formulated into cosmetic preparations, pharmaceuticals, quasi-drugs, foods, and the like.
Knee osteoarthritis is the most common joint disease affecting the joint itself as well as the peri-articular structures in a global and progressive manner. It can affect all the joints of the body, with a predominance for those which undergo strong mechanical constraints such as the rachis, the hip or the knee. It is a chronic pathology correlated with age, since nearly one adult in two is affected by osteoarthritis.

Today, connected objects have taken a predominant place in the daily life of the majority of the population, including seniors. It is an object of communication and socialization as well as a major information tool. E-health applications are more and more numerous in the stores and are a tool for assistance, information and support already used in many fields. In the context of therapeutic education, it is a motivational tool that can accompany patients by adapting to their needs and progress compared to traditional self-exercise methods. Studies of the obstacles and levers for the use of smartphone applications in chronic pathologies such as low back pain support the development of this tool.
Objective: To delineate the clinical characteristics and outcomes associated with severe cardiac toxicity during the preconditioning phase of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with aplastic anemia (AA). Methods: This retrospective case series study included 31 patients with severe AA who underwent allo-HSCT and were diagnosed with severe cardiac toxicity at the Hematology Department of Peking University People's Hospital from August 2012 to June 2022. The clinical manifestations of severe cardiac toxicity observed during the preconditioning process were assessed. Patient survival was assessed using the Kaplan-Meier method. Results: In this cohort of 31 patients, the median follow-up period was 9 days (range: 4-365 days). Severe cardiac toxicity manifested within 6 days after the initial cyclophosphamide (Cy) administration. Twenty patients died within 30 days of initiating Cy preconditioning, of which 16 patients died due to severe cardiac toxicity within 25 days. Patients whose cardiac function improved within 30 days post-preconditioning showed a median survival duration of 222 days (n=11). Troponin I (TNI) levels in patients who died within 30 days of initiating Cy preconditioning began increasing on day 5 post-Cy, peaking sharply by day 9 after a notable rise on day 8. B-type natriuretic peptide (BNP) levels in patients who died within 30 days of initiating Cy preconditioning started to rise from day 1, stabilized between days 2 and 5, and then doubled daily from days 6 to 8, remaining elevated thereafter. Notably, the initial increases in BNP and TNI correlated with electrocardiogram (ECG) signs of low voltage and T-wave inversion in 83.87% of cases (n=26). Most patients (n=28, 90.32%) were administered corticosteroid therapy. In those with restored cardiac function, the ejection fraction returned to >50% within 30 days of initiating Cy preconditioning. Conclusions: Patients with severe cardiac toxicity during the preconditioning phase of allo-HSCT typically exhibit early, sustained, and marked elevations in myocardial damage markers, including BNP and TNI, accompanied by ECG abnormalities following Cy administration, with BNP often increasing first. These indicators are associated with rapid disease progression and high mortality. Prompt initiation of treatment upon clinical diagnosis is critical for improving survival outcomes.
The invention relates to a western and Chinese medicine powder for externally treating pressure ulcers, which belongs to western and Chinese medicine preparation for external application and mainly solves the curing problem of pressure ulcers. The powder is prepared from the following raw materials as active ingredients by weight: 10 to 30 of Bletilla striata, 15 to 30 of membrane of hen egg, 10 to 30 of cutch, 10 to 30 of frankincense, 10 to 30 of phellodendron, 5 to 20 of metronidazole, 5 to 20 of vitamin C and 5 to 20 of nicotinic acid. The part with pressure ulcers is matted with a rubberized cloth, and sterilized dressing is put on the pressure ulcers for keeping the pressure ulcers sterilized. Firstly 3% of hydrogen peroxide solution is extracted with a disposable sterile syringe for washing the pressure ulcers from top down for several times till the pressure ulcers are clean so as to inhibit the growth of anaerobic bacteria; when a water blister appears, a sterile syringe is used for extracting liquid inside the water blister; when necrotic tissues are formed, sterile forceps and sterile scissors are used for cleaning the necrotic tissues; then 3% of hydrogen peroxide solution is used for washing the pressure ulcers from top down till the pressure ulcers are clean; after that, the prepared western and Chinese medicine powder is applied to the pressure ulcers with a disinfected swab, and the thickness of the powder is 1mm; the pressure ulcers are covered with a sterile Vaseline gauze and then dressed with sterilized dressing so as to prevent the pressure ulcers from scabbing rapidly; and the dressing is changed every day for avoiding local compression. When new tissues grow out, physiological saline is adopted for washing the affected part, and then the powder is applied without dressing. The pressure ulcers heal when the formed scab falls off.
Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
RATIONALE: Congenital butyrylcholinesterase deficiency (BCHED) is a rare autosomal recessive genetic disorder caused by a pathogenic mutation in the BCHE gene. Patients with BCHED may experience prolonged apnea or even death after the application of drugs such as succinylcholine. We aimed to identify the genetic basis of disease in a patient presenting with butyrylcholinesterase deficiency in order to confirm the diagnosis, expand BCHE gene mutation spectrum, and elucidate potential genotype-phenotype associations to inform management.
PATIENT CONCERNS: A 51-year-old woman presented with "vague pain in the upper and middle abdomen." Her serum cholinesterase level was 211 U/L (reference value 4000-13,000 U/L). Other laboratory findings were normal. Genetic analysis revealed compound heterozygous mutations in BCHE gene, which was considered pathogenic in this case.
DIAGNOSES: The patient presented with low serum cholinesterase levels, which excluded common causes such as liver disease, drug toxicity, and chronic illness. Whole exon examination revealed compound heterozygous mutations in the BCHE gene; thus, the patient was diagnosed with congenital BCHED.
INTERVENTIONS: Gastroscopy without succinylcholine or mivacurium chloride was recommended. The gastroscopy results were "gastric polyps," and gastroscopic "polypectomy" was performed. The patient was advised to avoid succinylcholine use.
OUTCOMES: The patient's serum cholinesterase level was reviewed 3 months later, and the result was 215 U/L. Double heterozygous mutations are the cause of BChE deficiency of this woman in this study, including a novel mutation NM_000055.4: c.666_669del (p.Phe223Glufs*38). A review of the literature reveals considerable variation in the hotspot variants of the BCHE gene across different populations. The Chinese population displays a higher prevalence of the silent type, which is more sensitive to anesthetics such as succinylcholine.
LESSONS: Clinical manifestations of congenital BCHED were not significant. This study avoided a potential anesthetic accident, and the novel variant enriched the BCHE gene mutation spectrum.
PURPOSE: A method for preparing extract derived from young barley leaf is provided to isolate novel ingredients and to be used as a functional material supply source. CONSTITUTION: A young barley leaf extract with an antioxidative activity is prepared using an organic solvent. The young barley leaf is collected in a length of 10-20 cm and is freeze-dried. The organic solvent is methanol or ethanol. The ethanol is 80-90 weight% ethanol solution. A composition for skin whitening or anti-aging contains the extract as an active ingredient. A health food for skin whitening or anti-aging contains the extract as an active ingredient. A solvent fraction of the extract contains one or more compounds selected from compound of chemical formulas 1-4.
The invention provides an extraction method and application of jellyfish collagen. The marine organism-derived collagen is a biological material which has more advantages than mammal collagen, and the antigenicity of the marine organism-derived collagen is weaker than that of the terrestrial mammal-derived collagen and the marine organism-derived collagen is easy to extract. The marine organism-derived collagen has better biological safety, does not cause mammal-derived diseases and pathogen transmission risks, does not relate to religious belief problems and has sufficient source. The extraction method of jellyfish collagen related by the invention mainly comprises the steps of desalination, pulping, degreasing, alkalization, enzyme extraction, centrifugation, salting out, centrifugation, precipitation redissolution, alkaline solution dialysis, pure water dialysis, freeze drying and the like. The extracted collagen presents white filiform powder and is aggregated into white sponge-state solid, the water solubility is good, and the collagen has extremely high similarity with human collagen in components. The jellyfish collagen prepared by the invention can be applied to the product fields of wound repair materials, artificial skin, beauty masks, cosmetics, implantable medical materials, health-care food and the like.
Patients inhale 7 drops of bergamot essential oil using an essential oil administration bottle TID (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
This is a parallel arm placebo-controlled clinical trial. We aim to include 84 adult patients with their first or second episode of Clostridioides difficile (formerly Clostridium difficile) infection. All patients receive vancomycin standard therapy. Patients are randomised in a 1:1 ratio to two treatments with capsules that contain either FMT+FMT or placebo+placebo. The primary outcome is absence of C difficile-associated disease 8 weeks after randomisation. Patients who have fulminant disease where it is deemed unethical to give placebo are offered open-label FMT. The primary outcome in patients with fulminant C difficile infection is 8 weeks mortality.
Umbilical cord care will be carried out using alcohol 70º at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
For each cohort in both study parts, 2 subjects will be randomized to control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
Patients in this group will do intermittent fasting dieting for 12 weeks, meaning they will only eat for 8 hours per day. They may choose whichever 8 hours they want. Only water can be consumed during the fasting period. For the last 12 weeks of the study, they will resume their normal diet.
The invention discloses a camellia oil extract moisturizing and moisture-preserving cream and a preparation method thereof. According to the invention, the tea seed oil deodorized distillate is extracted by refining the crude tea seed oil, so that the moisturizing effect of the face cream is improved. The deodorized distillate is modified to enhance the effect of phytosterol on skin in cream, prevent skin dryness and sclerosis, and soften keratinized skin. The bile acid ionic micelle can promote the absorption of skin on fatty acid, and reduce the effects of cream and water. The organosilicon modified polyurethane is added to reduce the moisture in the cream and enhance the cohesiveness and permeability of the cream. The camellia seed oil extract moisturizing and moisture-preserving cream disclosed by the invention realizes the maximum effect of moisturizing and moisture-preserving on skin.
Doravirine is a novel non-nucleoside reverse transcriptase inhibitor that has demonstrated good efficacy, tolerability, and safety for the treatment of patients with HIV infection in phase III clinical trials. Doravirine achieved non- inferiority when compared with efavirenz- and darunavir/ritonavir-based regimens. Doravirine is mainly metabolized and eliminated by the liver, with only 6% of the drug being excreted unchanged through the urine.In a study comparing 8 subjects with severe renal disease to 8 subjects without renal impairment, the single dose exposure of doravirine was 43% higher in subjects with severe renal function impairment.However, according to prescribing information, no dosage adjustment of doravirine is required in patients with mild, moderate, or severe renal impairment. On the other hand, data on doravirine pharmacokinetics in patients with ESRD on dialysis are lacking. This may be of special interest because doravirine has a relatively low molecular weight and it is only 76% bound to proteins in plasma. These characteristics could make possible for hemodialysis to remove doravirine from plasma, potentially leading to subtherapeutic concentrations of doravirine after the dialysis sessions. On the contrary, doravirine volume of distribution is about 60 liters,15 what could limit extraction of doravirine by hemodialysis. Since data on doravirine pharmacokinetics in PLWH with ESRD on dialysis are lacking, our aim is to evaluate the effect of intermittent hemodialysis on doravirine concentrations in HIV-infected patients with ESRD.
The trial will include a lead-in phase for each cohort to assess safety. In Cohort A, 10 patients will receive ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle. If no unexpected toxicities occur, Cohort A will open to enrollment. Enrollment for Cohort A will be done in two stages (after the lead-in portion is completed). The first stage for Cohort A will enroll a total of 22 patients (this will include the 10 patients from the lead-in phase). If there are at least 3 responses during stage 1, enrollment for stage 2 will proceed. For stage 2 of the study, 17 additional patients will be enrolled (for a total of 39 patients in Cohort A). During stage 1 and stage 2, patients in Cohort A will receive treatment with ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of each 21-day treatment cycle. Treatment will continue until disease progression or unacceptable toxicity occurs.

After the lead-in phase for Cohort A is completed, a similar lead-in portion, also consisting of 10 patients, will be done for Cohort B. Patients in Cohort B will receive ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle. If no unexpected toxicities occur in this group, Cohort B will open to enrollment. Enrollment for Cohort B will also be done in two stages (after the lead-in portion is completed). The first stage for Cohort B will enroll a total of 22 patients (this will include the 10 patients from the lead-in phase). If there are at least 3 responses during stage 1, enrollment for stage 2 will proceed. For stage 2 of the study, 17 additional patients will be enrolled (for a total of 39 patients in Cohort B). During stage 1 and stage 2, patients in Cohort B will receive treatment with ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of each 21-day treatment cycle. Treatment will continue until disease progression or unacceptable toxicity occurs.

Unexpected toxicities include any grade 4 hematologic toxicity or grade 3/4 non hematologic toxicity that does not reverse within 7 days in more than 2 patients.

Eligible patients will receive ixabepilone, carboplatin, and bevacizumab (bevacizumab will be administered to patients in Cohort B only) at 21-day intervals. Patients will be re evaluated every 6 weeks using computerized tomography (CT) scans. Response to therapy will be assigned using Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al. 2000) (see Section 7). Patients who have objective response or stable disease will continue treatment for 6 cycles, until the time of tumor progression or intolerable treatment-related side effects. Patients in Cohort B without progressive disease will be eligible to receive bevacizumab monotherapy for 6 additional cycles, or until undue toxicity or tumor progression occurs.
Benzodiazepines, levo-dopa/carbidopa, dopamine agonists, anticonvulsants, and opioids have been used with variable success, to treat RLS. Often, RLS patients treated with a benzodiazepine, over the course of several months, develop tolerance to the medication. Also, benzodiazepines can cause confusion or daytime sleepiness and may be addictive. Patients may also develop tolerance to levo-dopa/carbidopa treatment. Because of the short half-life, symptoms may be suppressed for only the first part of the sleep period and then recur later during the night. Rebound has been reported. Worse yet, augmentation, the occurrence of RLS symptoms, often more severe than before treatment began, earlier in the day, may occur in up to 80% of RLS patients treated with levod-dopa/carbidopa. Dopamine agonists, including pergolide, pramipexole, and ropinirole, are effective for some patients but not for others. Common side effects of these drugs include coryza, hypotension, and rash. Of the anticonvulsants, preliminary reports suggest that gabapentin, carbamazepine, and divalproex can suppress RLS symptoms in some patients, especially those with mild RLS. Side effects include sleepiness, ataxia, and weight gain. Opioid treatment for RLS has been described as effective but, aside from the stigma of taking controlled substances regularly, side effects may include nausea, sedation, constipation, and dysequilibrium. Iron supplementation is therapeutic in some patients with iron deficiency and RLS.

Preliminary anecdotal data suggest that topiramate reduces RLS symptoms. Topiramate has several potential mechanisms of action including enhancement of GABA-mediated inhibition, which may account for the observed benefit in patients with RLS.

Topiramate may be a better alternative than the currently available treatments to suppress RLS symptoms. Like gabapentin, it offers the possibility of decreasing RLS symptoms while also diminishing pain, especially in those patients who have limb pain from neuropathy, radiculopathy, or other causes. Unlike gabapentin, topiramate may help overweight patients with RLS lose weight, if anedotal reports on weight reduction with the medication are correct.
INTRODUCTION: Previous research found metaphor impairments with dyslexia; however, it is unclear if difficulties are due to initial activation of the metaphorical meaning or to subsequent discourse integration processes. The study examines the presence of early automatic processing of metaphors in adults with developmental dyslexia, considering the role of executive functions and metaphor familiarity.
METHODS: Using a sentence recall task and a semantic judgment task from the Metaphor Interference Effect (MIE) paradigm, we evaluated two early stages of metaphor comprehension, namely the generation of the figurative meaning and the suppression of the literal meaning. High and low familiar metaphors, and their scrambled counterparts, were aurally presented to participants, who were asked to judge whether sentences were literally true or literally false. Afterwards, they were provided ten minutes to recall the sentences they heard to verify the depth of processing for each type of stimulus. A total of 26 participants with dyslexia were included in the experimental group, and 31 in the control group.
RESULTS: Individuals with dyslexia showed a MIE and an accuracy rate that are similar to participants without dyslexia. Inhibition correlated with the MIE size only for high familiar metaphors, and working memory seemed to play no role in the process. In the recall task, both groups demonstrated a better encoding of the metaphorical sentences compared to scrambled metaphors, but participants with dyslexia recalled less metaphors than did the control group, showing that metaphors are no exception to the limitations in sentence retrieval typically found in dyslexia.
CONCLUSIONS: Our findings suggest that individuals with dyslexia are comparable to participants without dyslexia in their ability to automatically compute metaphorical meanings. Thus, difficulties in metaphor comprehension in people with dyslexia that have been detected in previous studies might depend on meaning construction in context rather than online semantic processing.